New Data Confirms That a Selective, Fully Human Anti-VEGF Antibody Being Developed by Peregrine is as Effective as Avastin(R) in Preclinical Can...( -- Data Presented at Anti-Angiogenes...),Health

-- Data Presented at Anti-Angiogenesis Conference Shows R84, the Selective

Human Anti-VEGF Antibody Developed by Peregrine in Association with Affitech, Is Equivalent to Avastin in Inhibiting Growth of Established

Tumors in a Preclinical Breast Cancer Model --

-- R84 Is Being Advanced as a Potential Clinical Candidate --

BOSTON and TUSTIN, Calif., Nov. 13 /PRNewswire-FirstCall/ -- Peregrine Pharmaceuticals, Inc. (Nasdaq: PPHM) a clinical stage biopharmaceutical company developing targeted monoclonal antibodies for the treatment of cancer and hepatitis C virus (HCV) infection, today reported that preclinical data presented at IBC's 5th Annual International Anti-Angiogenesis Conference showed that its anti-VEGF antibody R84 was as effective as Avastin(R) (bevacizumab) in inhibiting tumor growth in a mouse model of human breast cancer. R84 is a selective, fully human monoclonal antibody that blocks the cancer-promoting agent vascular endothelial growth factor (VEGF). R84 selectively blocks VEGF from binding only to VEGF receptor 2 (VEGFR2), while non-selective agents such as Avastin block binding to both VEGFR2 and VEGF receptor 1 (VEGFR1). Selective anti-VEGF agents may have potential advantages over non-selective approaches and Peregrine is now assessing R84 as a candidate for clinical development. R84 is a product of the collaboration between Peregrine and antibody developer Affitech AS of Oslo, Norway.

The data demonstrating the potential anti-cancer efficacy of R84 in xenograft models of human cancer was part of a presentation by Dr. Rolf Brekken, assistant professor of surgery and pharmacology and Effie Marie Cain Scholar in Angiogenesis Research at UT Southwestern Medic
'/>"/>